CeNeS Licenses MS Treatment to Acorda
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 31 (Table of Contents)
Published: 2 Dec-2002
DOI: 10.3833/pdr.v2002.i31.963 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
CeNeS Pharmaceuticals licensed its preclinical recombinant GGF2 protein for treating multiple sclerosis to Acorda Therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS